Bioconnect Systems was established to develop innovative techniques for creating connections and sealing conduits throughout the body. The company has developed the Optiflow System which offers surgeons the ability to create precisely controlled connections for a variety of clinical indications.
Allos Therapeutics, Inc. (NASDAQ: ALTH) is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company has two product candidates in late-stage clinical development: EFAPROXYN (efaproxiral), a radiation sensitizer currently under evaluation in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer, and PDX (pralatrexate), a novel, next generation antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma.
Dendreon Corporation (Nasdaq: DNDN) is a Seattle-based biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. Through innovative science and technology, we are striving to develop and commercialize products that address unmet medical need, improve survival and have a favorable safety profile.